Overview

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety

Status:
Completed

Trial end date:
2015-02-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the painkilling efficacy of ASP8477 relative to mock (placebo) in patients that have been diagnosed with painful diabetic peripheral neuropathy or postherpetic neuralgia determined by the change in the average daily pain intensity in patients that initially respond favorably to treatment with ASP8477.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

ASP8477